University at Buffalo (UB)


The University at Buffalo is a leading public research university and flagship of the SUNY System, recognized for its innovative research and commitment to societal impact. It aims to transform scientific and technological breakthroughs into global impact, addressing complex challenges through interdisciplinary collaboration.

University at Buffalo (UB)

University at Buffalo (UB)

875 Ellicott St., 6th floor, Downtown Campus, Buffalo, NY 14203


What We Do

Support for finding research funding, preparing grant proposals, administering awards, and compliance.

Facilitating collaborations between businesses and the university for innovation and economic development.

Providing training on electronic systems utilized to support research activities and compliance.

A collaborative initiative to harness AI for public good, launched at UB's Center for Computational Research.

A new facility funded by a $7.3 million NIH grant to study the oral microbiome and systemic diseases.

A center focused on improving early literacy instruction using AI, awarded $10 million.



Key People

Satish K. Tripathi

President

LinkedIn

Timothy F. Murphy

Director of UB’s Community Health Equity Research Institute

Vice President, Research and Economic Development

Associate Vice President for Research Administration

Director of CCR

Research Connector for Industry Partnerships


News & Updates

UB is now eligible to compete for up to $160 million in federal investment for its AI and health equity initiatives.

Funding to help early career faculty address health disparities in the region.

This is a monumental victory for the Buffalo-Rochester-Syracuse region as the first major Tech Hub award in the nation.

The initial computing power for Empire AI has been installed at UB’s Center for Computational Research, allowing members to begin harnessing AI for public good.

The new Center for Early Literacy and Responsible AI will focus on harnessing AI to transform early literacy instruction for diverse learners.

Abceutics was founded by Joseph P. Balthasar and colleagues in 2020, improving the safety and efficacy of an important emerging class of cancer drugs.